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Background: Long noncoding RNAs (lncRNA) are key regulators of gene transcription and many show tissue-specific expression. We pre-
viously defined a novel inflammatory and metabolic ileal gene signature in treatment-naive pediatric Crohn disease (CD). We now extend our 
analyses to include potential regulatory lncRNA.
Methods: Using RNAseq, we systematically profiled lncRNAs and protein-coding gene expression in 177 ileal biopsies. Co-expression analysis 
was used to identify functions and tissue-specific expression. RNA in situ hybridization was used to validate expression. Real-time polymerase 
chain reaction was used to test lncRNA regulation by IL-1β in Caco-2 enterocytes.
Results: We characterize widespread dysregulation of 459 lncRNAs in the ileum of CD patients. Using only the lncRNA in discovery and inde-
pendent validation cohorts showed patient classification as accurate as the protein-coding genes, linking lncRNA to CD pathogenesis. Co-expression 
and functional annotation enrichment analyses across several tissues and cell types 1showed that the upregulated LINC01272 is associated with 
a myeloid pro-inflammatory signature, whereas the downregulated HNF4A-AS1 exhibits association with an epithelial metabolic signature. We 
confirmed tissue-specific expression in biopsies using in situ hybridization, and validated regulation of prioritized lncRNA upon IL-1β exposure in 
differentiated Caco-2 cells. Finally, we identified significant correlations between LINC01272 and HNF4A-AS1 expression and more severe mucosal 
injury.
Conclusions: We systematically define differentially expressed lncRNA in the ileum of newly diagnosed pediatric CD. We show lncRNA utility 
to correctly classify disease or healthy states and demonstrate their regulation in response to an inflammatory signal. These lncRNAs, after mech-
anistic exploration, may serve as potential new tissue-specific targets for RNA-based interventions.
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INTRODUCTION
The inflammatory bowel diseases (IBDs), Crohn disease 
(CD) and ulcerative colitis (UC), are caused by a complex inter-
action between host genetic background, microbial shifts, and 
environmental cues, leading to chronic activation of the mucosal 
immune system.1–3 Meta-analysis identified 163 different IBD risk 
loci,4 and a more recent analysis added 38 new loci.5 The majority 
of those IBD susceptibility loci are intergenic or intronic. These 
data are in agreement with the ENCODE project,6 showing that a 
large fraction of risk for complex disease is driven by noncoding 
genetic variation. Among those, approximately 10% of disease-as-
sociated single nucleotide polymorphisms (SNPs) are mapped to 
genomic loci encoding long noncoding RNAs (lncRNAs).7, 8
LncRNAs play fundamental roles in gene transcription 
regulation9, 10 and overall exhibit more tissue-specific expression 
patterns than protein-coding genes. They are a large (>15,00011) 
and diverse class of non-protein-coding genes longer than 200 
nucleotides. Emerging data have highlighted their regulation of 
immunity.12 LncRNA are differentially regulated in virus-in-
fected cells13 and in monocytes after lipopolysaccharide stimu-
lation.14 The lncRNA NeST controls susceptibility to Theiler’s 
virus and Salmonella infection in mice through epigenetic regu-
lation of the interferon-γ (IFN-γ) locus,13 and long interspersed 
ncRNA (lincRNA)–Cox2 acts as a broad-acting regulatory com-
ponent of a circuit that controls the inflammatory response.14 
Hrdlickova et  al.15 revealed lncRNA enrichment in several 
immune-related disorders including IBD. Specifically, micro-
array analysis from colon biopsies of adults with long-standing 
IBD showed widespread dysregulation of lncRNA in inflamed 
and noninflamed tissue.16 However, there are no studies char-
acterizing lncRNA in the ileum of treatment-naive (not influ-
enced by treatment), early-onset pediatric CD patients.
The Crohn’s and Colitis Foundation of America (CCFA)–
sponsored RISK study is a prospective inception cohort study 
that enrolled 1098 pediatric CD patients at diagnosis at 28 sites 
in North America between 2008 and 2012.17, 18 All patients were 
treatment naive, with ileal biopsies obtained during the initial 
diagnostic colonoscopy. Using RISK RNAseq data and UCSC 
annotation, we have previously characterized transcriptomic sig-
natures associated with CD pathogenesis focusing on protein-cod-
ing genes.17 We defined a core ileal CD (iCD) signature enriched 
for genes induced by bacterial products and pro-inflammatory 
cytokine signaling, including IFNγ, whereas genes induced by 
several nuclear receptors, including HNF4α, were suppressed. 
Functional analyses identified enrichment of innate antimicro-
bial responses and a profound loss of nuclear receptor–dependent 
lipid metabolic functions. However, differentially expressed lncR-
NAs that may play a central role in regulating the transcriptional 
landscape in a tissue-specific manner have not yet been defined. 
Here, we extend our analyses using GENCODE/ENCODE and 
Ensembl (http://useast.ensembl.org) annotation to characterize 
differentially expressed protein-coding and lncRNAs, extend-
ing the CD signature to now include 459 differentially expressed 
lncRNA genes. Importantly, we show that those lncRNAs can be 
utilized to correctly classify disease or healthy states in patients 
undergoing diagnostic endoscopies. We put forward a way to pri-
oritize differentially expressed lncRNAs for future analyses, elab-
orate on their potential functions and tissue-specific expression, 
and validate specific prioritized lncRNA expression and regula-
tion upon IL-1β triggering. As lncRNAs show higher tissue-spe-
cific expression in comparison with protein-coding genes, these 
tissue-specific lncRNA, after mechanistic exploration, may serve 
as potential new targets for RNA-based interventions that will be 
associated with fewer off-target toxic effects.
MATERIAL AND METHODS
The RISK Cohort
Ileal biopsy RNAseq and associated clinical information 
were obtained from the RISK study,17, 19–22 an ongoing, prospec-
tive observational IBD inception cohort sponsored by the CCFA. 
Newly diagnosed patients were enrolled and required to undergo 
baseline colonoscopy and confirmation of characteristic chronic 
active colitis/ileitis by histology before diagnosis and treatment.
RNA-seq Expression and Gene Enrichment 
Analysis
Ileal RNA extraction and mRNA-seq were performed 
as previously described (GEO series accession number 
GSE57945),17 with some modification as noted. To include 
lncRNAs in the analyses, reads were quantified by kallisto,23 
using Gencode v23 as the reference genome and transcripts 
per million (TPM) as an output. Only 20,326 transcripts with a 
TPM above 1 in 20% of the samples were included in our down-
stream differential expression analysis. Samples were stratified 
into specific clinical subgroups including control (Ctl) and CD 
with ileal inflammation (iCD). Those groups were age- and gen-
der-matched and were randomly assigned (ratio 4:1) to discov-
ery or independent validation groups (Table  1). Differentially 
expressed genes were determined by the moderated t test method 
in GeneSpring next-generation sequencing software using the 
Benjamini–Hochberg false discovery rate correction (FDR, 
0.05), and analyzed for fold change differences (FC) ≥1.5. Log2-
transformed and baselined-to-median-level Ctl values were used 
for unsupervised hierarchical clustering using the Euclidean dis-
tance metric and Ward’s linkage rule to test for groups of ileal 
biopsies with similar patterns of gene expression. Pearson cor-
relation based on trend and rate of change was performed for 
selected lncRNAs as indicated for a correlation co-efficient of 
0.75 < r < 1. ToppGene24 and ToppCluster25 software were used 
to test for enrichment of groups of genes within biologically rele-
vant pathways. Visualization of the network was obtained using 
Cytoscape.v3.0.226 and the ReVIGO approach, which converts 
a list of Gene Ontology terms into a semantic, similarity-based 
scatterplot after removing redundant terms.27 LncRNA prior-
itization was based on at least an average of 1 TPM in Ctl or 
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iCD and showed the highest fold change differences between 
iCD and Ctl. Further prioritization of the top 15 differentially 
expressed lncRNAs was based on the highest number of genes 
that coexpressed with the lncRNAs in our cohort. FASTQ files 
from human-derived peripheral blood cells (GSE6465528) and 
human-derived intestinal biopsies (E-MTAB-173329) were ana-
lyzed using the same pipeline. Similar RNA extraction, RNAseq, 
and analysis pipelines were applied on the differentiated Caco-2 
cells samples. Those samples’ data were deposited in GSE94578.
Caco-2 Cells
Caco-2 human colon carcinoma cell line was purchased 
from the American Type Culture Collection (Manassas, VA, 
USA) and maintained in standard culture conditions in DMEM 
(GIBCO 41965-039, Scotland) containing 20% (v/v) heat-inac-
tivated fetal bovine serum (GIBCO 12657-029, Scotland). For 
experiments, cells were seeded on 6-well ThinCerts—0.4-um 
plate (Greiner bio-one 657641, Austria) for 21 days to obtain 
fully differentiated cells, and transepithelial electrical resistance 
(TEER) values were measured (World Precision Instruments, 
FL). Differentiated Caco-2 cells were either left untreated 
or treated with 25  ng/mL of IL-1β (MerckMillipore Human 
Recombinant Animal Free GF331, Germany). Cell fractiona-
tion was done using the PARIS kit (Thermo Fisher Scientific, 
CA, USA) according to the manufacturer’s directions.
Expression (Quantitative Polymerase Chain 
Reaction) Studies
Total RNA was isolated using Tri Reagent-LS (Sigma, T9424, 
Saint Louis, MO, USA). RNA concentration and purity were 
assessed on a NanoDrop ND-1000 spectrophotometer (Thermo 
Fisher Scientific, Wilmington, DE, USA). First-strand cDNA 
was synthesized using a high-capacity RNA-to-cDNA reverse 
transcription kit (Applied Biosystems, 4387406). Quantitative real-
time polymerase chain reaction (qPCR) was performed using a 
Fast SYBR Green Master mix (Applied Biosystems, 4385612) and 
qPCR machine with standard qPCR parameters to analyze the 
expression of indicated genes compared with the control gene 
GAPDH (primer list is in Supplementary Table 10). Results were 
analyzed with the comparative CT method, and log10 (relative 
quantification values [Rq] values) are shown.30, 31
In Situ Hybridization
3’ end biotin-labeled probes (Integrated DNA 
Technologies, Leuven, Belgium), recognizing HNF4A-AS1 
and LINC01272, and a scrambled control probe were used at 
180 nM for in situ hybridization on formalin-fixed, paraffin-em-
bedded ileal biopsies. The alkaline phosphatase conjugate 
streptavidin (Roche, 11093266910,  Basel, Switzerland)  with 
subsequent BCIP/NBT color development substrate (Roche, 
11681451001, Basel, Switzerland) was used to obtain the stain-
ing. A positive probe and a negative probe were included in the 
assay for quality control.
Ethical Considerations
The institutional review board at each site reviewed and 
approved the protocol, and informed written consent or assent 
was obtained in all cases from parents or guardians. All patients 
provided appropriate assent. This study was approved by na-
tional regulatory authorities and by local ethics committees or 
institutional review boards.
RESULTS
Widespread Dysregulation of Protein-Coding 
and lncRNAs in the Ileum of Treatment-Naive 
Pediatric CD Patients Using RNAseq and 
GENCODE/Ensembl Annotation
The majority of lncRNAs are generated by similar tran-
scriptional machinery as mRNA, with a 5’ methylguanosine 
TABLE 1. Clinical and Demographic Characteristics
Ctl Discovery (n = 30)
CD
Discovery
(L1,L3, n = 111)
Ctl Validation 
(n = 8)
CD Validation
(L1,L3, n = 28)
Age, mean (SD), y 11.2 (3) 11.9 (3) 11 (5) 12.2 (3)
Male gender, % 60 61 62 61
Mixed European descent (MED) ethnicity (3 of 4 
grandparents), %
87 81 89 79
PCDAI ≤ 10 (inactive), % — 8 — 11
PCDAI 11 to 30 (mild), % — 39 — 36
PCDAI ≥ 31 (moderate-severe), % — 53 — 53
Ileal deep ulcers, % — 53 — 46
Abbreviations: L1, ileal location; L2, colon-only location; L3, ileo-colonic location; PCDAI, Pediatric Crohn Disease Activity Index at diagnosis before treatment.
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cap, and are often spliced and polyadenylated.9 We were there-
fore able to utilize our previously published ileal biopsy poly-A 
selected RNAseq data set (GEO series accession number 
GSE57945) of subjects with newly diagnosed CD and non-IBD 
controls to test for differences in lncRNA expression (Table 1 
and Supplementary Table 1). This includes CD patients with 
clinically affected (ileal CD [iCD], n  =  139) ilea and non-
IBD Ctl (n = 38). CD patients and Ctl participants were ran-
domly divided and age- and gender-matched to the discovery 
(80%) and independent validation (20%) iCD and Ctl cohorts 
(Table  1). However, for more comprehensive analyses of the 
lncRNA, instead of using the UCSC annotation as a reference 
for alignment and quantification, we used the GENCODE/
ENCODE project11 implemented into Ensembl (V23, GRCh38, 
Ensembl 81)  as our reference. One main advantage of using 
the GENCODE/Ensembl annotation is that it clearly classifies 
each annotated gene as a protein coding or noncoding gene. 
The GENCODE v23 (GRCh38, Ensembl 81) version includes 
60,498 genes; 19,797 protein-coding genes, 15,931 long non-
coding genes, 9882 small noncoding genes, 14,477 pseudogenes, 
and 411 immunoglubulin/T-cell receptor genes. For quantifica-
tion, we used kallisto software.23
Our analyses comparing the iCD and Ctl ileal discovery 
samples identified 3022 genes (Supplementary Table  2) that 
were differentially expressed (FDR  <  0.05 and fold change 
≥1.5) (Supplementary Table  2 and Supplementary Fig.  1A). 
Unsupervised hierarchical clustering identified groups of 
patients with similar ileal gene expression profiles; this analysis 
tested whether patients with CD cluster together, whereas the 
transcriptional profile of non-IBD Ctl patients would cluster 
together. Unsupervised hierarchical clustering of the discovery 
cohorts showed that all Ctl patients grouped in cluster 1 and 
most of the CD patients grouped in cluster 2 (Supplementary 
Fig. 1B). We also applied principal component analysis (PCoA) 
as another approach to view patients’ separation using specific 
gene expression profiles, an approach that is used to reduce 
dimensionality of the input data. Loading the 3022 differen-
tially expressed genes and the top 3 dimensions showed that 
most Ctl patients were separated from most of the CD patients 
(Supplementary Fig. 1C). Of note, although we used Ensembl 
annotation instead of the UCSC annotation that we previ-
ously used,17 we were able to show that >85% of the previously 
reported genes17 are within the new 3022 genes list. However, 
although our previously reported list contained <50 lncR-
NAs, using our current approach we identified 10 times more 
lncRNAs.17
Significant Enrichment of Known IBD-Associated 
SNPs Within Differentially Expressed and 
Annotated lncRNA
Similar to previously reported data,16 we tested for the 
presence of known IBD-associated SNPs (total of 233 SNPs) 
within annotated lncRNAs. We identified IBD loci-associated 
lncRNAs genes by intersecting the IBD susceptibility loci, 
which was defined as a 500-kb long genomic region with the 
IBD risk variant in the middle. In total, 1051 IBD loci-asso-
ciated lncRNAs were identified, out of which 41 unique lncR-
NAs were found to be differentially expressed (Supplementary 
Table 3). These differentially expressed 41 lncRNAs co-local-
ized with 47 unique IBD risk variants, and were found to be 
enriched within IBD loci (P < 0.0001, chi-square test).
LncRNAs Can Be Utilized to Correctly Classify 
Disease or Healthy States in Patients Undergoing 
Diagnostic Endoscopies
Classification of the 3022 genes into gene biotypes based 
on GENCODE annotation is shown in Table  2 and includes 
2160 protein coding genes (71%) and 459 lncRNAs (15%). 
Table  2 further subdivided the lncRNAs into specific types. 
Unsupervised hierarchical clustering using only the 459 lncR-
NAs demonstrated that all discovery Ctl samples grouped in 
cluster 1 and most of the discovery CD patients grouped in 
cluster 2 (Fig. 1A), similar to clustering using the entire 3022 
genes (Supplementary Fig. 1). PCoA to view patients’ separa-
tion using the 459 differentially expressed lncRNAs and the 
top 3 dimensions showed that most Ctl patients are separated 
from most of the CD patients (Fig. 1B). Importantly, unsuper-
vised hierarchical clustering using only the 459 lncRNAs on an 
independent validation cohort also demonstrated that all Ctl 
samples grouped in cluster 1 and most of the validation CD 
patients grouped in cluster 2 (Fig. 1C), and PCoA showed that 
most Ctl patients are separated from most of the CD patients 
(Fig. 1D). Interestingly, we noted that a higher fraction of the 
lncRNAs (83%, 380/459, of the lncRNAs) was downregulated 
TABLE 2. Differentially Expressed Ileal Gene Types
Gene Type
Number of Genes
(n = 3022)
Protein coding genes 2160
LncRNA lncRNA type 459
3’ UTR overlapping 1
Antisense 184
LincRNA 219
Processed transcript 30
Sense intronic 19
Sense overlapping 6
IG/TR 234
Pseudogenes 150
TEC 19
Abbreviations: IG/TR, immunoglobulin/T cell receptors; TEC, transcripts to be ex-
perimentally confirmed; UTR, untranslated region.
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in iCD vs Ctl (Fig. 1E) in comparison with the fraction of the 
downregulated protein-coding genes (51%, 1099/2160).
Supervised classification algorithms may be used to de-
velop models to classify unknown patient groups based on gene 
expression data that differ within a training set of known pa-
tient groups. The Support Vector Machine (SVM) algorithm is 
a machine learning approach, which is commonly used to clas-
sify 2 patient classes based on differential expression of biologic 
data. We conducted a supervised classification analysis using the 
2160 protein-coding genes and 459 lncRNA genes differentially 
expressed between iCD and Ctl on a discovery cohort compris-
ing 111 iCD and 30 Ctl patients to develop a classification model 
using the SVM algorithm (80% of the samples) (Table 1). We 
then tested the accuracy of the model on an independent valid-
ation cohort of 28 iCD and 8 Ctl (Table 3). Applying the model 
to the discovery and independent validation cohorts resulted 
in comparable accuracy using the 459 lncRNA and 2160 pro-
tein-coding genes (Table  3). Importantly, those unsupervised 
(hierarchical clustering and PCoA) and supervised (SVM algo-
rithm) analyses of discovery and validation cohorts further link 
altered expression of lncRNA to CD pathogenesis.
Prioritizing the Differentially Expressed lncR-
NAs Based on Highest Fold Change and 
Co-expression Analyses
Our initial prioritization of differentially expressed 
lncRNA was based on the highest fold change differences 
between iCD and Ctl (Tables 4 and 5) and focused on the top 15 
down- and 15 upregulated ileal lncRNA. Within our pediatric 
treatment-naïve cohort, we identified CDKN2B-AS1 (ANRIL) 
lncRNA, previously shown to regulate gene transcription in 
cis (in vicinity) and in trans (at distant loci) in carcinogenesis 
and cardiovascular disease, as one of the top 15 downregu-
lated genes. Interestingly, CDKN2B-AS1 was within the top 10 
downregulated transcripts in the colon of treated adult patients 
with IBD, whereas downregulation of HNF4A-AS1 lncRNA 
was unique to our ileal cohort. We also identified LINC01272 
and RP11-44K6.2 within our 15 top ileal upregulated lncRNAs 
that were also within the top 10 upregulated lncRNA tran-
scripts in the colon of adult IBD patients.16
Co-expression analyses32, 33 of  lncRNAs with well-char-
acterized protein-coding mRNA is usually used to gain insights 
into lncRNA potential functions. As we were interested in pri-
oritizing potential functional lncRNA, we used co-expression 
as another factor for prioritization. We further prioritized the 
top 15 differentially expressed lncRNAs to those that show 
co-expression with the larger set of  genes, as a read out for 
their potential functionality. We used Pearson correlation 
analyses (r  >  0.75) to identify co-expression of  lncRNAs 
within our Ctl and iCD samples. Of  the top 15 downregu-
lated genes, both HNF4A-AS1 and CDKN2B-AS1 showed 
the highest number of  co-expressed genes (Table 4). The 314 
HNF4A-AS1 downregulated co-expressed genes remarkably 
overlapped with the 411 CDKN2B-AS1 co-expressed gene 
list (>80%) and included 3 other lncRNAs (CDKN2B-AS1, 
RP11-116D2.1, and RP11-132E11.2) also within the top 15 
downregulated lncRNAs. Of the top 15 upregulated lncR-
NAs, LINC01272 showed the highest number of  187 upregu-
lated co-expressed genes (Table 5).
Prioritized Differentially Expressed HNF4A-AS1 
lncRNAs Show Epithelial-Specific Expression and 
Associations With Metabolic Functions
Many lncRNAs exhibit tissue-specific expression pat-
terns.34 We therefore assessed the expression of prioritized 
LINC01272 and HNF4A-AS1 expression in independent 
noninflamed tissues and cells including publically available 
RNAseq of human blood–derived cell types (GSE6465528) and 
human-derived intestinal tissues (E-MTAB-173329). We supple-
mented those analyses with RNAseq of our local differentiated 
TABLE  3. Accuracy of Support Vector Machine Model 
on Discovery and Independent Validation Ctl and iCD 
Samples
Discovery Cohort
Accuracy, % 459 lncRNA Genes
2160 Protein- 
Coding Genes
Ctl (n = 30) 83 90
iCD (n = 111) 98 96
Overall (n = 141) 95 95
Independent Validation 
Cohort Accuracy, %
459 lncRNA Genes 2160 Protein- 
Coding Genes
Ctl (n = 8) 75 100
iCD (n = 28) 96 100
Overall (n = 36) 92 100
FIGURE 1. Differentially expressed ileal lncRNA perform well in sample classification. A, Hierarchical clustering of the 459 differentially expressed 
ileal lncRNA genes was performed on a discovery set (n = 111 iCD and 30 Ctl; fold change of ≥1.5 and corrected P < 0.05) and visualized as a heat 
map with genes upregulated compared with controls in red and genes downregulated compared with controls in blue. Above the heat map, indi-
vidual Ctl (blue) and iCD (red) samples are indicated. B, 459 differentially expressed lncRNA genes were used to view Ctl (blue) and iCD (red) patients’ 
samples, separated by training cohort, on a principal component analysis plot. C, Hierarchical clustering of the 459 differentially expressed ileal 
lncRNA genes was performed on a validation cohort (n = 36) and visualized as a heat map as in (A). Above the heat map, individual Ctl (blue) and 
iCD (red) samples are indicated. D, 459 differentially expressed lncRNA genes were used to view validation cohort Ctl (blue) and iCD (red) patients’ 
samples, on a principal component analysis plot. E, Fraction of the up- (gray) and downregulated (black) differentially expressed genes within the 
459 lncRNA and 2160 protein-coding genes. A significantly higher fraction of the lncRNA were downregulated in comparison with protein coding 
genes (X2 = 180.9, P < 0.001).
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Caco-2 intestinal epithelial cell lines. Caco-2 cells, although 
derived from the colon, when differentiated and polarized, 
exhibit a phenotype, tissue marker expression, morphology, 
and cellular functions that resemble small intestine enterocytes. 
Indeed, in this independent data set, we show high expression 
of HNF4-AS1 in small intestinal tissue (duodenum and ileum) 
and Caco-2 cells, remarkably low expression in neutrophils, and 
no expression (TPM level < 1 and read count < 10,) in other 
cells and tissues (Fig. 2A).
To gain insights into those lncRNA potential func-
tions, we employed co-expression analyses32 also in those new 
samples and tested for co-expression of lncRNA with well 
characterized protein-coding mRNA. We used Pearson cor-
relation analyses (r > 0.75) to identify co-expression and then 
TABLE 4. Top 15 Downregulated Differentially Expressed Ileal lncRNA Genes
Top 15 Downregulated FC (iCD) vs Ctl Ensembl Gene ID lncRNA Subclass Remark Co-expression
RP11-347E10.1 –13.2 ENSG00000254416 lincRNA 97
FOXD1-AS1 –9.9 ENSG00000247993 lincRNA 1
RP11-64D22.5 –8.6 ENSG00000250271 lincRNA 35
RP11-91P17.1 –8.3 ENSG00000254001 lincRNA 2
CDKN2B-AS1 –7.4 ENSG00000240498 antisense also in adult 
colon
411
RP11-116D2.1 –7.1 ENSG00000261012 lincRNA 265
RP11-245G13.2 –6.8 ENSG00000271952 lincRNA 1
RP11-132E11.2 –6.5 ENSG00000237153 lincRNA 78
HNF4A-AS1 –6.1 ENSG00000229005 antisense 314
RP11-143A12.3 –6.1 ENSG00000250198 lincRNA 134
RP11-689K5.3 –5.9 ENSG00000251331 lincRNA 1
RP11-1223D19.1 –5.9 ENSG00000261760 lincRNA 1
RP11-122K13.7 –5.6 ENSG00000226699 antisense 1
RP11-798K3.2 –5.6 ENSG00000259347 lincRNA 156
RP11-680F8.1 –5.5 ENSG00000256802 antisense 200
Abbreviations: Co-expression, number of additional differentially expressed ileal genes co-expressed with the lncRNA by Pearson correlation analysis; FC, fold change between 
iCD and control.
TABLE 5. Top 15 Upregulated Differentially Expressed Ileal lncRNA Genes
Top 15 Upregulated FC (iCD) vs Ctl Ensembl Gene ID LncRNA Subclass Remark Co-expression
CTB-61M7.2 16.9 ENSG00000268734 lincRNA 30
RP11-598F7.3 11.1 ENSG00000256948 antisense 1
LUCAT1 10.4 ENSG00000248323 lincRNA 67
LINC01272 9.4 ENSG00000224397 lincRNA also in adult colon 187
RP11-290L1.3 7.9 ENSG00000257453 antisense 1
LINC00694 6.9 ENSG00000225873 lincRNA 1
RP11-44K6.2 5.3 ENSG00000253838 sense_intronic also in adult colon 1
LINC01235 5.2 ENSG00000270547 lincRNA 1
FAM225A 5.2 ENSG00000231528 lincRNA 152
RP11-536O18.1 4.4 ENSG00000226197 lincRNA 1
RP11-115D19.1 4.1 ENSG00000251095 antisense 1
LINC00582 4.1 ENSG00000229228 antisense 1
WISP1-OT1 4.0 ENSG00000270132 sense_intronic 1
RP11-638I2.8 4.0 ENSG00000258666 antisense 1
CTD-2589M5.4 4.0 ENSG00000255007 antisense 1
Abbreviations: Co-expression, number of additional differentially expressed ileal genes co-expressed with the lncRNA by Pearson correlation analysis; FC, fold change between 
iCD and control.
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conducted functional annotation enrichment analyses to map 
groups of related genes to identify biological process, pathways, 
phenotypes, and molecular functions, where P values for the 
specific pathway, phenotype, and function were obtained as 
an output from ToppGene.24 Pearson correlation analyses on 
those tissues and cells identified 4102 genes that co-expressed 
with HNF4A-AS1 (Supplementary Table  4). Uunsupervised 
hierarchical clustering for this gene set is shown in Fig.  2B, 
showing clear separation between small intestine and differ-
entiated Caco-2 cells and neutrophils. Functional annotation 
enrichment analyses of those 4102 genes showed enrichment 
for Gene Ontology Biological Process terms involving epithelial 
development (P < 7.94E-5) and functions including the organic 
acid metabolic process (P < 4.15E-13), but also enrichment for 
Continued
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ncRNA processing (P < 4.15E-13) and translation (P < 8.42E-
7) (Fig. 2C and Supplementary Table 4). Those results are vis-
ualized using the ReVIGO approach,27 which converts a list of 
Gene Ontology terms into a semantic, similarity-based scatter-
plot after removing redundant enrichment terms.
Prioritized Differentially Expressed LINC01272 
Show Specific Myeloid Expression and 
Association With Myeloid Immune Activation
In this independent data set, we show high expression of 
linc01272 to myeloid dendritic cells (DCs), monocytes (Mo), 
peripheral blood mononuclear cells (PBMCs), and neutrophils, 
and to a lesser degree to human-derived intestinal tissues and T 
cells, but no expression (TPM level < 1 and read count < 10) in B 
cells and Caco-2 cells (Fig. 2D). Performing Pearson correlation 
analyses (r > 0.75) on those tissues and cells identified 521 genes 
that co-expressed with LINC01272. Uunsupervised hierarchical 
clustering of this gene set is shown in Fig. 2E, sowing clear sep-
aration between myeloid cells and PBMCs from the intestinal 
tissues, NK cells, and T cells. Functional annotation enrichment 
analyses of those 521 genes (Supplementary Table  5) showed 
enrichment for Gene Ontology Biological Process terms involv-
ing inflammatory and immune response (P  <  1.96E-26) and 
more specifically myeloid functions (P < 4.43E-13) and response 
to bacteria (P < 1.68E-10) (Fig. 2F and Supplementary Table 5).
To validate HNF4A-AS1 and LINC01272 cell-spe-
cific expression and to test their subcellular localization, we 
employed RNA in situ hybridization on paraffin sections using 
HNF4A-AS1 antisense Biotin-labeled oligonucleotides probes. 
Consistent with the expression data, HNF4A-AS1 is specifi-
cally expressed in the epithelia, showing predominantly nuclear 
staining in those cells (Fig. 2G). In contrast, LINC01272 show 
no expression in epithelia, but are expressed in immune cells 
scattered in the intestinal lamina propria (Fig. 2H). Our obser-
vations regarding tissue-specific expression of LINC01272 to 
leukocytes and HNF4A-AS1 to epithelia are further supported 
by the publicly available GTEx RNAseq database, where 
HNF4A-AS1 showed the highest expression in small intestine 
and liver tissues and LINC01272 showed the highest expression 
in whole blood and spleen (Supplementary Fig. 2).
Validation of the Functional Annotation 
Enrichment Analyses of HNF4A-AS1 and 
LINC01272 lncRNAs Within Our Cohort
To support those lncRNA potential functions and 
validate the above co-expression analyses, we employed 
FIGURE 2. Expression and functional annotation enrichment analyses of the HNF4A-AS1 and LINC01272 co-expression networks in diverse cellular 
and tissue samples. A, HNF4A-AS1 TPM levels in several human-derived noninflamed peripheral blood cells (n = 2, PBMC, B cells, T cells, neutrophil, 
monocyte, NK cells, myeloid DC). Noninflamed intestinal tissues are shown (3 stomach, 2 duodenum [Duo], 4 small intestine [SI], 3 colon), and 
unstimulated differentiated Caco-2 cells. B, Hierarchical clustering of the 4102 genes that co-expressed with HNF4A-AS1 (expressed above 1 TPM and 
10 read count) in the indicated cells and tissues is shown and visualized as a heat map, with genes higher and lower than the median levels of all 
samples in red and blue, respectively. C, The top 50 Gene Ontology (GO): Biological Process terms found for the HNF4A-AS1 co-expression network 
were visualized using the ReVIGO approach, which converts a list of gene ontology terms into a semantic, similarity-based scatterplot after remov-
ing redundant terms. Bubble color indicates P value; size indicates the frequency of the GO term in the underlying GOA database (more general 
terms are larger). The full list of genes and the functional enrichment results and P values are in Supplementary Table 4. D, LINC01272 TPM levels in 
several human-derived peripheral blood cells and intestinal tissues are shown. E, Hierarchical clustering of the 521 genes that co-expressed with 
LINC01272 (expressed above 1 TPM and 10 read count) in the indicated cells and tissues is shown and visualized as a heat map, with genes higher 
and lower than the median levels of all samples in red and blue, respectively. F, Top 50 GO: Biological Process terms found for the LINC01272 co-ex-
pression network were visualized using ReVIGO approach as in (C). The full list of genes and the functional enrichment results and P values are in 
Supplementary Table 5. G, RNA in situ hybridization detection of HNF4A-AS1 in paraffin-embedded sections of ileal mucosal biopsies. Dark purple 
staining of HNF4A-AS1 is located predominantly in the epithelia nucleus. H, RNA in situ hybridization detection of LINC01272 in paraffin-embedded 
sections of ileal mucosal biopsies. Dark purple staining of LINC01272 is located predominantly in the nucleus of immune cells scattered in the intesti-
nal lamina propria.
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co-expression analyses and functional annotation enrichment 
analyses also within our Ctl and inflamed CD ileal samples. 
Pearson correlation (r > 0.75) analysis identified 314 downreg-
ulated genes that co-express with HNF4A-AS1 (Supplementary 
Table 6). Functional annotation of these 314 suppressed genes 
(Fig. 3A and Supplementary Table 7) showed enrichment for 
entities associated with the organic acid metabolic process 
(P < 1.5E-17), lipid metabolic process (P < 2.16E-14), oxida-
tion-reduction process (P < 7.54E-12), vitamin digestion and 
absorption (P  <  4.67E-7), and brush border cellular compo-
nent (P  <  6.13E-26). Interestingly, functional annotation to 
transcription factor binding sites showed top enrichment for 
HNF4 (P < 5.6E-4). To model the effect of the inflammatory 
signal on prioritized lncRNA in an epithelial model system, 
we stimulated Caco-2 cells with IL-1β (25 ng/mL), which were 
previously shown to be upregulated in the ileum of patients 
with CD17. As expected, we noted an increased expression of 
IL8 after incubation with IL-1β. We also detected a signifi-
cantly increased expression of DUOX2 and decreased expres-
sion of APOA1 (Fig. 4), similar to the increased and decreased 
expression detected in the ileum of CD patients.17 We further 
detected a significant decrease of CDKN2B-AS1, RP11-
132E11.2, RP11-347E10.1, and RP11-798E3.2 in the Caco-2 
system after IL-1β stimulation, as was observed in CD biop-
sies in comparison with Ctl. Importantly, both CDKN2B-AS1 
and HNF4A-AS1 showed enrichment to the nuclear fraction in 
the Caco-2 model system like the established nuclear lncRNA 
MALAT1, which may suggest a transcriptional regulatory role 
in intestinal epithelia (Supplementary Fig. 3).
Pearson correlation analysis identified 187 upregu-
lated genes that co-express with the upregulated LINC01272 
(Supplementary Table 8). Functional annotation of these 187 
genes (Fig. 3B and Supplementary Table 9) showed enrichment 
for entities associated with inflammatory response (P < 2.32E-
29), response to the molecule of bacterial origin (P < 7.12E-
26), CD11b activated granulocyte myeloid cells (P < 4.36E-69), 
cytokine activity (P < 5.36E-10), and immunoglobulin binding 
(P < 2.44E-6). Altogether, combining co-expression and func-
tional enrichment analyses indicated a predominant epitheli-
al-related signature of those downregulated CDKN2B-AS1 and 
HNF4A-AS1 co-expressed lncRNAs, in contrast to the gran-
ulocyte-associated signature of the upregulated LINC01272. 
This was in agreement with our results across a diverse set of 
noninflamed tissues and cells (Fig. 2).
HNF4A-AS1 and CDKN2B-AS1 Expression 
Significantly Correlates With More Severe 
Mucosal Injury
We tested for correlation between LINC01272 and 
HNF4A-AS1 and clinical disease activity indices and the sever-
ity of mucosal injury. Using the Pediatric Crohn’s Disease 
Activity Index (PCDAI) as a continuous value or stratify-
ing the iCD group to those inactive (PCDAI ≤ 10), with mild 
symptoms (PCDAI ≤ 30), and with moderate-severe symptoms 
(PCDAI > 30) at diagnosis showed no significant correlation 
or differences, respectively, for both LINC01272 expression 
and HNF4A-AS1 expression (Fig.  5). However, dividing the 
iCD group into 2 groups based on the presence of deep ulcers 
(DU, iCD-DU, and iCD-noDU), which are associated with 
endoscopic severity scaling and unfavorable clinical outcome,35 
demonstrated a significant increase of LINC01272 in iCD-DU 
in comparison with iCD-noDU (Fig. 6). These results are fur-
ther supported by the significant positive correlation noted 
between S100A8 (calprotectin), our best current clinical bio-
marker for tissue inflammation, and LINC01272 (r  =  0.9, 
FIGURE 4. Prioritized CD-associated lncRNA and protein-coding genes 
are regulated by IL-1β in Caco-2 cells. Caco-2 cells were differentiated 
on transwell inserts and were either left untreated or treated with 
IL-1β (25 ng/mL) for 24 hours. Prioritized CD-associated downregu-
lated lncRNA and protein-coding mRNA were determined by qPCR of 
mRNA. Relative quantification values (Rq) were compared between 
IL-1β and untreated cells (n = 6), and log10(Rq) values (mean with SEM) 
are presented. Paired t test (1-tailed) was performed on the delta cycle 
threshold values (Ct) of specific genes compared with the control gene 
GAPDH. *P < 0.05, **P < 0.01, ***P < 0.001.
FIGURE 3. Functional annotation enrichment analyses of the HNF4A-AS1 and LINC01272 co-expression networks. A, Functional annotation 
enrichment analyses of the HNF4A-AS1 co-expression network using ToppGene/ToppCluster25 and Cytoscape26 are shown. GO: Biological Process 
(blue), GO: Pathways (green), GO: Cellular Component (turquoise), and Transcription Factor Binding Site (pink). The full list of gene set enrichment 
results and P values is in Supplementary Table 7. B, Functional annotation enrichment analyses of the LINC01272 co-expression network using 
ToppGene/ToppCluster25 and Cytoscape26 are shown: GO: Biological Process and GO: Molecular Function (blue) and immune cell (light green) 
using the Immunological Genome Project data series through ToppGene/ToppCluster. The full list of gene set enrichment results and P values is in 
Supplementary Table 9.
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P  <  0.001). In contrast, a significant negative correlation 
with S100A8 was noted with HNF4A-AS1, and a significant 
decrease of HNF4A-AS1 expression was observed in iCD-DU 
vs iCD-no DU (Fig. 6). These results emphasize that lncRNAs 
show positive correlation with tissue inflammation and lack of 
correlation with clinical disease activities (PCDAI). These sig-
nificant correlations between lncRNA expression and mucosal 
tissue injury further highlight the need to elucidate their poten-
tial function in CD pathogenesis as a first step toward utilizing 
those lncRNAs as targets for potential future interventions.
DISCUSSION
We previously defined a core ileal CD (iCD) signature 
enriched for genes coding for innate antimicrobial responses 
and a profound loss of nuclear receptor–dependent lipid met-
abolic functions.17 However, differentially expressed lncRNAs 
that may play a central role in regulating the transcriptional 
landscape in a tissue-specific manner have not yet been defined. 
Growing evidence suggests that lncRNAs contribute to vari-
ous aspects of gene regulation in the immune system. However, 
there are only a few studies focusing on lncRNAs in human 
gut pathogenesis,16, 36 and specifically, there are no studies of 
the ileum of treatment-naive pediatric CD patients. Here, based 
on the largest prospective pediatric treatment-naive inception 
cohort, we extend the CD signature to now include 459 dif-
ferentially expressed lncRNA genes. We show that lncRNA 
can be utilized to correctly classify disease or healthy states in 
patients undergoing diagnostic endoscopies. Prioritizing differ-
entially expressed genes based on the highest fold change dif-
ferences, and more uniquely to our study on higher numbers of 
co- expressed genes, directed us to epithelial-specific and mye-
loid-specific lncRNA expression and potential functions. We 
validated the lncRNA-specific expression using in situ hybrid-
ization in intestinal biopsies. Finally, we captured a significant 
correlation between HNF4A-AS1 and LINC01272 expression 
and a presence of more severe mucosal ulcers. Those results are 
illustrated in Fig. 7. The tissue specificity of lncRNA may offer 
a clear interventional advantage as a future pharmacologic tar-
get that will have a less off-target toxic effect.
The rapid growth of  genome-wide transcriptome data 
sets has uncovered a fast-growing list of  lncRNAs (>15,000). 
FIGURE 5. HNF4A-AS1 and LINC01272 lncRNA show no correlation with the Pediatric Crohn’s Disease Activity Index. A, LINC01272 log10(TPM) of 
iCD patients (n = 139) were plotted against their Pediatric Crohn’s Disease Activity Index as a continuous value at diagnosis (right) or after stratify-
ing the iCD group to those inactive (n = 12, PCDAI ≤ 10), with mild symptoms (n = 53, PCDAI ≤ 30), and with moderate-severe symptoms (n = 74, 
PCDAI > 30) at diagnosis. Log10(TPM) levels of Ctl (n = 38) are shown for comparison. B, HNF4A-AS1 log10(TPM) of iCD patients were plotted against 
their PCDAI as a continuous value (right) or after stratifying the group, as in (A). Log10(TPM) levels of Ctl are shown for comparison.
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However, most of  those lncRNAs are uncharacterized, and 
their associations with human pathogenesis are only begin-
ning to emerge. LncRNA differential expression in the colon 
of  adult patients has only recently been associated with CD 
and UC using microarray analyses.16, 36 We have been using 
RNAseq rather than microarray and propose a pipeline for 
lncRNA identification using Ensembl/Gencode annotation 
and lncRNA prioritization. Using Ensembl/Gencode anno-
tation, we were able to capture 10 times more lncRNAs than 
using the UCSC annotation.17 We show similar altered down-
regulation of  CDKN2B-AS1 and upregulation of  LINC01272 
in the CD ileum, as was previously reported in the colon of 
UC and CD patients16, 36 within our top 15 down- and upreg-
ulated lncRNAs and the previously reported downregulation 
of  DIO3OS (Supplementary Table 2), supporting the valid-
ity of  our approach. However, we identified HNF4A-AS1, 
which shows remarkably high expression specific to the 
small intestine and Caco-2 cells in the enterocytes system, 
and we confirmed its expression to predominantly the epi-
thelial nucleus. We also show that 41 differentially expressed 
lncRNA genes co-localized with 47 IBD risk variant loci and 
are enriched within IBD loci. Those 41 lncRNAs included 
our prioritized lncRNAs LINC01272 and HNF4A-AS1. 
Interestingly, and unlike previously described data in the 
colon of  UC patients who show an increase of  329 lncRNAs 
and a decrease of  126 lncRNAs in active UC tissues com-
pared with normal controls, we noticed a significantly higher 
fraction of  the lncRNAs (83% of  the total 459 differentially 
expressed lncRNA) to be decreased in active ileal CD (iCD) 
mucosa in comparison with controls. This observation was 
unique to lncRNAs in the ileum as an equal number of  pro-
tein coding-genes (51%) were downregulated in iCD vs Ctl 
(Fig. 2) in the same samples. H19 and SPRY4-IT1 lncRNAs 
have both been recently associated with the regulation of 
FIGURE 6. HNF4A-AS1 and LINC01272 lncRNA show significant correlation with severity of mucosal injury and with ileal S100A8 gene expression. A, 
LINC01272 log10(TPM) of all patients (iCD [n = 139] and Ctl [n = 38]) were plotted against their log10(TPM) of S100A8 as a continuous value (right) or 
after stratifying the iCD group to those with or without deep ulcers (iCD-DU [n = 72] and iCD-noDU [n = 67], respectively). B, HNF4A-AS1 log10(TPM) 
of all patients plotted against their log10(TPM) of S100A8 as a continuous value (right) or after stratifying the iCD group, as in (A). Analysis of vari-
ance with Bonferroni’s multiple comparison test was calculated for the stratified groups, and Pearson correlation was calculated for the continuous 
variables. *P < 0.05, **P < 0.01, ***P < 0.001.
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intestinal epithelial barrier function.37, 38 As co-expression 
analyses suggest that the downregulated gene signal is com-
ing from the epithelia, it will be highly important to further 
understand the role of  the remarkably decreased lncRNA 
expression on epithelial integrity and repair.
There is a clear necessity in the IBD field for novel drugs 
that target major pathogenic pathways with minimal toxicities. 
The 12-month remission rate with currently available treatments 
is below 65%39 and is associated with increased risk for cancer 
and infections. While anti–tumor necrosis factor (anti-TNF) 
and newer antibodies offer effective medications, these drugs 
substantially increase the economic cost of IBD treatment. 
Moreover, at least for anti-TNF treatment, only 50% will main-
tain long-term remission,40 in part due to development of antid-
rug antibodies that reduce the effect of the drug. RNA-based 
therapies conjugated to cholesterol to facilitate cellular uptake 
are currently being evaluated in clinical trials for different disor-
ders including IBD.41, 42 A specific inhibitor of miR-122 showed 
prolonged dose-dependent reductions in HCV RNA levels 
without evidence of viral resistance,43 and Mongersen, an oral 
SMAD7 antisense oligonucleotide, was shown in a double-blind 
phase II clinical trial to be efficacious in active CD.42 One 
advantage in harnessing lncRNA-directed therapy is its higher 
tissue specificity expression in comparison with protein-coding 
genes, which should be associated with fewer off-target effects. 
Along those lines, we have captured a specific expression of 
HNF4A-AS1 to epithelial cells, and LINC01272 to myeloid DC, 
monocytes, and neutrophils. Another advantage in targeting 
lncRNA is their potential key regulatory role on gene transcrip-
tion. CDKN2B-AS1 (ANRIL) lncRNA has previously been 
shown to regulate gene transcription in cis (in vicinity) and in 
trans (at distant loci) in carcinogenesis and cardiovascular dis-
ease, whereas the role of the other prioritized lncRNAs is not 
yet known and will be tested in future studies. An important 
future approach to better characterize lncRNA function will 
include employing specific modulations of HNF4A-AS1 and 
CDKN2B-AS1 levels. This approach will provide strong evi-
dence of a transcriptional role in intestinal epithelia, which is 
more convincing than showing expression alone.
In conclusion, we define differentially expressed lncRNAs 
in the ileum of treatment-naive pediatric CD patients. We show 
lncRNA utility to correctly classify disease or healthy states in 
both discovery and independent validation cohorts. We prior-
itized lncRNA and confirmed their tissue-specific expression 
FIGURE 7.  Graphical summary of the cohort and main findings. Using the largest prospective pediatric treatment naïve inception cohort, we 
extend the CD signature to now include 459 differentially expressed lncRNA genes. We show that lncRNA can be utilized to correctly classify disease 
or healthy states. Prioritizing differentially expressed gene based on highest fold change differences, and more uniquely to our study on higher 
number of co-expressed genes, directed us to epithelial-specific and myeloid-specific lncRNA expression and potential functions.
 Inflamm Bowel Dis • Volume 24, Number 2, February 2018
360
Haberman et al
and demonstrate their regulation in response to an inflam-
matory signal in an enterocyte model system. Characterizing 
lncRNA expression is the first step toward elucidating lncR-
NAs’ molecular mechanisms, which will provide further more 
comprehensive insights into CD pathogenesis and ultimately 
lead to novel therapeutic strategies.
ACKNOWLEDGMENTS
This work was part of M. BenShoshan’s PhD thesis. 
We thank the Crohn’s and Colitis Foundation RISK study 
publication committee for critical review of this manuscript.
REFERENCES
1. Aujnarain A, Mack DR, Benchimol EI. The role of the environment in the 
development of pediatric inflammatory bowel disease. Curr Gastroenterol Rep. 
2013;15:326.
2. Molodecky NA, Soon IS, Rabi DM, et al. Increasing incidence and prevalence 
of the inflammatory bowel diseases with time, based on systematic review. 
Gastroenterology. 2012;142:46–54.e42; quiz e30.
3. Kim SC, Tonkonogy SL, Karrasch T, et al. Dual-association of gnotobiotic il-10-
/- mice with 2 nonpathogenic commensal bacteria induces aggressive pancolitis. 
Inflamm Bowel Dis. 2007;13:1457–1466.
4. Jostins L, Ripke S, Weersma RK, et al; International IBD Genetics Consortium 
(IIBDGC). Host-microbe interactions have shaped the genetic architecture of 
inflammatory bowel disease. Nature. 2012;491:119–124.
5. Liu JZ, van Sommeren S, Huang H, et  al; International Multiple Sclerosis 
Genetics Consortium; International IBD Genetics Consortium. Association anal-
yses identify 38 susceptibility loci for inflammatory bowel disease and highlight 
shared genetic risk across populations. Nat Genet. 2015;47:979–986.
6. Dunham I; ENCODE Project Consortium. An integrated encyclopedia of DNA 
elements in the human genome. Nature. 2012;489:57–74
7. Carpenter S. Long noncoding RNA: novel links between gene expression and 
innate immunity. Virus Res. 2016;212:137–145.
8. Kumar V, Westra HJ, Karjalainen J, et  al. Human disease-associated genetic 
variation impacts large intergenic non-coding rna expression. Plos Genet. 
2013;9:e1003201.
9. Mercer TR, Mattick JS. Structure and function of long noncoding RNAs in epi-
genetic regulation. Nat Struct Mol Biol. 2013;20:300–307.
10. Nagano T, Fraser P. No-nonsense functions for long noncoding RNAs. Cell. 
2011;145:178–181.
11. Derrien T, Johnson R, Bussotti G, et al. The gencode v7 catalog of human long 
noncoding RNAs: analysis of their gene structure, evolution, and expression. 
Genome Res. 2012;22:1775–1789.
12. Hua Geng X-DT. Functional diversity of long non-coding RNAs in immune reg-
ulation. Genes Dis. 2016;3:72–81.
13. Polites SF, Habermann EB, Zarroug AE, et  al. a comparison of two qual-
ity measurement tools in pediatric surgery–the American College of Surgeons 
National Surgical Quality Improvement Program-pediatric versus the Agency 
for Healthcare Research and Quality pediatric quality indicators. j Pediatr Surg. 
2015;50:586–590.
14. Carpenter S, Aiello D, Atianand MK, et  al. a long noncoding rna medi-
ates both activation and repression of  immune response genes. Science. 
2013;341:789–792.
15. Hrdlickova B, Kumar V, Kanduri K, et al. Expression profiles of long non-coding 
RNAs located in autoimmune disease-associated regions reveal immune cell-type 
specificity. Genome Med. 2014;6:88.
16. Mirza AH, Berthelsen CH, Seemann SE, et al. Transcriptomic landscape of lncR-
NAs in inflammatory bowel disease. Genome Med. 2015;7:39.
17. Haberman Y, Tickle TL, Dexheimer PJ, et al. Pediatric Crohn disease patients 
exhibit specific ileal transcriptome and microbiome signature. j Clin Invest. 
2014;124:3617–3633.
18. Gevers D, Kugathasan S, Denson LA, et al. The treatment-naive microbiome in 
new-onset Crohn’s disease. Cell Host Microbe. 2014;15:382–392.
19. Walters TD, Kim MO, Denson LA, et  al; PRO-KIIDS Research Group. 
Increased effectiveness of  early therapy with anti-tumor necrosis factor-α 
vs an immunomodulator in children with Crohn’s disease. Gastroenterology. 
2014;146:383–391.
20. Cutler DJ, Zwick ME, Okou DT, et al; PRO-KIIDS Research Group. Dissecting 
allele architecture of early onset ibd using high-density genotyping. Plos One. 
2015;10:e0128074.
21. Rosen MJ, Karns R, Vallance JE, et al. Mucosal expression of type 2 and type 17 
immune response genes distinguishes ulcerative colitis from colon-only Crohn’s dis-
ease in treatment-naive pediatric patients. Gastroenterology. 2017;152:1345–1357.e7.
22. Kugathasan S, Denson LA, Walters TD, et al. Prediction of complicated disease 
course for children newly diagnosed with Crohn’s disease: a multicentre inception 
cohort study. Lancet. 2017;389:1710–1718.
23. Bray NL, Pimentel H, Melsted P, Pachter L. Near-optimal probabilistic rna-seq 
quantification. Nat Biotechnol. 2016;34:525–527.
24. Chen J, Bardes EE, Aronow BJ, Jegga AG. Toppgene suite for gene list 
enrichment analysis and candidate gene prioritization. Nucleic Acids Res. 
2009;37:W305–W311.
25. Kaimal V, Bardes EE, Tabar SC, et al. Toppcluster: a multiple gene list feature 
analyzer for comparative enrichment clustering and network-based dissection of 
biological systems. Nucleic Acids Res. 2010;38:W96–102.
26. Saito R, Smoot ME, Ono K, et  al. a travel guide to cytoscape plugins. Nat 
Methods. 2012;9:1069–1076.
27. Supek F, Bošnjak M, Škunca N, Šmuc T. revigo summarizes and visualizes long 
lists of gene ontology terms. Plos One. 2011;6:e21800.
28. Hoek KL, Samir P, Howard LM, et al. a cell-based systems biology assessment 
of human blood to monitor immune responses after influenza vaccination. PLoS 
One. 2015;10:e0118528.
29. Fagerberg L, Hallström BM, Oksvold P, et  al. Analysis of the human tis-
sue-specific expression by genome-wide integration of transcriptomics and anti-
body-based proteomics. Mol Cell Proteomics. 2014;13:397–406.
30. Livak K. Comparative Ct method. ABI Prism 7700 Sequence Detection System. 1997.
31. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time 
quantitative pcr and the 2(-delta delta c(t)) method. Methods. 2001;25:402–408.
32. Guttman M, Amit I, Garber M, et  al. Chromatin signature reveals over a 
thousand highly conserved large non-coding RNAs in mammals. Nature. 
2009;458:223–227.
33. Rinn JL, Chang HY. Genome regulation by long noncoding RNAs. Annu Rev 
Biochem. 2012;81:145–166.
34. Cabili MN, Trapnell C, Goff L, et al. Integrative annotation of human large inter-
genic noncoding RNAs reveals global properties and specific subclasses. Genes 
Dev. 2011;25:1915–1927.
35. Allez M, Lemann M, Bonnet J, et al. Long term outcome of patients with active 
Crohn’s disease exhibiting extensive and deep ulcerations at colonoscopy. Am j 
Gastroenterol. 2002;97:947–953.
36. Wu F, Huang Y, Dong F, Kwon JH. Ulcerative colitis-associated long noncoding 
rna, bc012900, regulates intestinal epithelial cell apoptosis. Inflamm Bowel Dis. 
2016;22:782–795.
37. Xiao L, Rao JN, Cao S, et al. Long noncoding rna spry4-it1 regulates intestinal 
epithelial barrier function by modulating the expression levels of tight junction 
proteins. Mol Biol Cell. 2016;27:617–626.
38. Zou T, Jaladanki SK, Liu L, et al. h19 long noncoding rna regulates intestinal 
epithelial barrier function via microRNA 675 by interacting with rna-binding 
protein hur. Mol Cell Biol. 2016;36:1332–1341.
39. Minar P, Haberman Y, Jurickova I, et al. Utility of neutrophil FCγ receptor i 
(cd64) index as a biomarker for mucosal inflammation in pediatric Crohn’s dis-
ease. Inflamm Bowel Dis. 2014;20:1037–1048.
40. Hanauer SB, Feagan BG, Lichtenstein GR, et  al; ACCENT I  Study Group. 
Maintenance infliximab for Crohn’s disease: the accent i randomised trial. Lancet. 
2002;359:1541–1549.
41. Wahlestedt C. Targeting long non-coding rna to therapeutically upregulate gene 
expression. Nat Rev Drug Discov. 2013;12:433–446.
42. Monteleone G, Pallone F. Mongersen, an oral smad7 antisense oligonucleotide, 
and Crohn’s disease. n Engl j Med. 2015;372:2461.
43. Polites SF, Zielinski MD, Zarroug AE, et al. Benchmarks for splenectomy in pedi-
atric trauma: how are we doing? j Pediatr Surg. 2015;50:339–342.
